Anti-GFAP (phospho S13) Antibody (RMAB-0250626)
Cat. No.: RMAB-0250626
Category: Primary Antibodies
INQUIRY
100 μL
10 µL
Rabbit monoclonal to GFAP (phospho S13)
Product Features
| Isotype | IgG |
|---|---|
| Clonality | Monoclonal |
| Host Species | Rabbit |
| Clone Number | EPR25281-65 |
| Form | Liquid |
| Purity | Protein A purified |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide. |
| Applications | WB, IHC-P, Flow Cyt (Intra), IP, Dot blot |
| Key Features | Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply; Rabbit monoclonal to GFAP (phospho S13); Suitable for: WB, IHC-P, Flow Cyt (Intra), IP, Dot blot; Reacts with: Human |
Target Information
| Target Symbol | GFAP |
|---|---|
| Target Name | Glial fibrillary acidic protein |
| UniProt ID | P14136 |
| Cellular Localization | Cytoplasm. Associated with intermediate filaments. |
| Function | GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells. |
| Involvement in Disease | Defects in GFAP are a cause of Alexander disease (ALEXD). Alexander disease is a rare disorder of the central nervous system. It is a progressive leukoencephalopathy whose hallmark is the widespread accumulation of Rosenthal fibers which are cytoplasmic inclusions in astrocytes. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death usually within the first decade. Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course. |
| Post-translational Modifications | Phosphorylated by PKN1. |
| Sequence Similarities | Belongs to the intermediate filament family. |
Storage & Shipping
| Storage Buffer | pH: 7.2; Preservative: 0.01% Sodium azide; Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA |
|---|---|
| Storage & Shipping | Shipped at 4°C. Store at 4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. |
For research use only. Not for clinical use.
